You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

 

Online download statistics by month:

Online download statistics by month: August 2021 to July 2025

AbstractFullPdf
Aug 202118718764
Sep 2021228229100
Oct 202110610626
Nov 2021949430
Dec 202116816823
Jan 2022565930
Feb 202210610918
Mar 2022545418
Apr 2022596019
May 2022646420
Jun 2022636327
Jul 2022585918
Aug 2022575711
Sep 2022656536
Oct 2022393917
Nov 2022464835
Dec 202225255
Jan 2023323216
Feb 2023565613
Mar 2023212220
Apr 2023232319
May 2023262613
Jun 2023303010
Jul 2023232316
Aug 202321215
Sep 2023171711
Oct 2023272717
Nov 2023363615
Dec 2023262711
Jan 2024424332
Feb 2024272822
Mar 2024373768
Apr 2024303019
May 2024323221
Jun 2024333214
Jul 2024464710
Aug 202414139
Sep 2024242724
Oct 2024293021
Nov 2024404119
Dec 202422239
Jan 2025363621
Feb 202519209
Mar 2025373821
Apr 2025585825
May 2025323320
Jun 2025222226
Jul 2025110
Total239424171053